 Home > Encyclopedia > Sulfamethoxydiazine

Sulfamethoxydiazine

Sulfamethoxydiazine structure

CAS No:
651-06-9
Formula:
C11H12N4O3S
Chemical Name:
Sulfamethoxydiazine
Synonyms:
Benzenesulfonamide,4-amino-N-(5-methoxy-2-pyrimidinyl)-;Sulfanilamide,N1-(5-methoxy-2-pyrimidinyl)-;4-Amino-N-(5-methoxy-2-pyrimidinyl)benzenesulfonamide;AHR 857;BAY 5400;2-(4-Aminobenzenesulfonamido)-5-methoxypyrimidine;Bayrena;Durenat;Kiron;Methoxypyrimal;N1-(5-Methoxy-2-pyrimidinyl)sulfanilamide;5-Methoxy-2-sulfanilamidopyrimidine;Sulfameter;Sulfamethoxine;Sulfamethoxydiazine;Sulfamethoxydin;Sulfamethoxypyrimidine;Sulfametin;2-Sulfanilamido-5-methoxypyrimidine;Sulla;Sulphamethoxydiazine;Sulphameter;Longasulf;SH 613;Berlicid;Kirocid;Ultrax;2-Sulfa-5-methoxypyrimidine;Sulfametoxydiazine;I 2586;Kinecid;Sulfametorine;5-Methoxysulfadiazine;NSC 683528;N-(5-Methoxypyrimidin-2-yl)-4-aminobenzenesulfonamide
Categories:
Organic Chemistry > Amides

Description

Sulfameter(Bayrena) is a long-acting sulfonamide antibacterial.Target: AntibacterialSulfameter(Bayrena) is a long-acting sulfonamide antibacterial. It is used as a leprostatic agent in the treatment of urinary tract infections.Six physically healthy patients each were given 2 g of sulfameter simultaneously with a high lipid, high protein and high carbohydrate test meal. This experiment was designed as a threefold crossover study, and there was a randomized assignment of patients to the d

Sulfamethoxydiazine is a sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antiinfective agent, a renal agent and a leprostatic drug. It is a member of pyrimidines, a sulfonamide and a sulfonamide antibiotic. It derives from a sulfanilamide.|Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.|Sulfameter is a long-acting sulfonamide antibacterial agent used to treat urinary tract infections and leprosy.

Sulfamethoxydiazine Basic Attributes

Molecular Weight：

280.31

Exact Mass：

280.30

EC Number：

211-480-8

UNII：

3L179F09D6

NSC Number：

757874|683528

DSSTox ID：

DTXSID5023613

NCI Thesaurus Code：

C66568

ATC Code：

J - Antiinfectives for systemic use

HScode：

2935009090

Characteristics

PSA：

116

XLogP3：

0.4

Appearance：

white with faint yellow cast

Density：

1.5±0.1 g/cm3

Melting Point：

214-216 °C

Boiling Point：

539.4°C at 760 mmHg

Flash Point：

280.0±31.8 °C

Refractive Index：

1.647

Water Solubility：

0.47g/L(30 ºC)

Storage Conditions：

2-8°C

Collision Cross Section：

159 Å² [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]|161.6 Å² [M+H]+ [CCS Type: TW, Method: calibrated with Waters Major Mix]|171.3 Å² [M+Na]+ [CCS Type: TW, Method: calibrated with Waters Major Mix]

Safety Information

Transport codes：

NONH for all modes of transport

wgk germany：

hazard class code：

36/37/38

safety instructions：

26-36

RTECS Number：

WP0525000

Marks：

Precautionary statement(s)：

P261-P305 + P351 + P338

Hazard Statements：

H315-H319-H335

GHS Classification：

|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 127 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

MeSH：

Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. (See all compounds classified as Leprostatic Agents.)|Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)|Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)

MeSH Entry Terms：

Sulfameter

Sulfamethoxydiazine Use and Manufacturing

Uses

An antibacterial

Use Classification：

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Pharmaceuticals

Computed Properties

Molecular Weight:280.31
XLogP3:0.4
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:4
Exact Mass:280.06301143
Monoisotopic Mass:280.06301143
Topological Polar Surface Area:116
Heavy Atom Count:19
Complexity:368
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This product is a long-acting sulfonamide drug, which has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae. The antibacterial mechanism is that it is similar to para-aminobenzoic acid (PABA) in structure and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria and reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purines, thymine nucleotides and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Sulfadimethoxine Tablets
Ingredients	The main component of this product is sulfamethoxazole, and its chemical name is: N-(5-methoxy-2-pyrimidinyl)-4-aminobenzenesulfonamide. Its molecular formula is: C11H12N4O3S, and its molecular weight is: 280.31.
Indication	1. Urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. Combination with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. Such as leukopenia and thrombocytopenia, etc. If there is an indication for the use of the two drugs together, possible toxic reactions should be closely observed. 5. Long-term combination with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7 When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8 When used in combination with photosensitive drugs, photosensitization may be additive. 9 Patients receiving this product have an increased need for vitamin K. 10 It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product. The risk of crystalluria increases. 11 This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12 When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, and its blood concentration increases and lasts for a long time, thereby producing toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the application of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of this product should be monitored to help adjust the dose and ensure safe medication.
Specifications	0.5g
Manufacturer	Datong Liqun Pharmaceutical Co., Ltd.

Sulfadimethoxine Tablets
Ingredients	The main component of this product is sulfamethoxazole, and its chemical name is: N-(5-methoxy-2-pyrimidinyl)-4-aminobenzenesulfonamide. Its molecular formula is: C11H12N4O3S, and its molecular weight is: 280.31.
Indication	1. Urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are antagonistic. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. Combination with bone marrow suppressive drugs may enhance the adverse reactions of such drugs to the hematopoietic system. Such as leukopenia and thrombocytopenia, etc. If there is an indication for the use of the two drugs together, possible toxic reactions should be closely observed. 5. Long-term combination with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7 When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8 When used in combination with photosensitive drugs, photosensitization may be additive. 9 Patients receiving this product have an increased need for vitamin K. 10 It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product. The risk of crystalluria increases. 11 This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12 When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, and its blood concentration increases and lasts for a long time, thereby producing toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the application of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of this product should be monitored to help adjust the dose and ensure safe medication.
Specifications	0.5g

Sulfadimethoxine
Manufacturer	Gooddoctor Pharmaceutical Group Co., Ltd.

See More Related Drugs

Registered Holders

Gooddoctor Pharmaceutical Group Co., Ltd.

China
Active

Recommended Suppliers of Sulfamethoxydiazine

HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Sulfameter

CAS No.: 651-06-9

Content: 99.00%

Inquiry